This is far greater than the 5-10% typically observed with currently prescribed obesity medications such as the 5 hydroxytryptamine 2C (5-HT2C) receptor agonist lorcaserin or the glucagon-like peptide 1 (GLP-1) analogue liraglutide and approaches that found with bariatric surgeries such as vertical sleeve gastrectomy (VSG) and Roux-en-Y gastric bypass (RYGB). The gene discussed is GCG; the disease is obesity disorder.